Drug intelligence / Profile preview

arzanol

Development stage
Preclinical
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

Arzanol is a prenylated phloroglucinol-α-pyrone heterodimer natural product isolated from the Mediterranean plant *Helichrysum italicum*. It functions as a multi-target small molecule with potent anti-inflammatory, antioxidant, and antimicrobial properties. Its primary mechanism involves the dual inhibition of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LOX), effectively blocking the biosynthesis of pro-inflammatory eicosanoids. Arzanol also modulates the NF-κB signaling pathway, activates SIRT1, and inhibits human dihydroorotate dehydrogenase (hDHODH) and brain glycogen phosphorylase. Research has explored its potential in treating inflammatory conditions, various cancers (notably bladder cancer), metabolic disorders, and viral infections including SARS-CoV-2. Currently in the preclinical stage, its development faces challenges such as high serum protein binding which impacts its pharmacokinetic profile.

Other names
prenylated phloroglucinol-alpha-pyrone heterodimer
02

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)NDUFS4 (NADH:ubiquinone oxidoreductase subunit S4)NF-κBbc1 complex (Cytochrome bc1 complex (plasmodium))PTGES (Microsomal prostaglandin E synthase-1)PYGB (Glycogen phosphorylase, brain form)

Beyond the preview

Go deeper on arzanol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on arzanol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call